Chris Shaw

Title: The Innovative Contributions of Chris Shaw

Introduction

Chris Shaw is a notable inventor based in Comber, GB. He has made significant contributions to the field of pharmaceuticals, particularly through his research on bradykinin B2-receptor antagonist peptides. His work has implications for treating various disorders, showcasing the importance of innovation in medical science.

Latest Patents

Chris Shaw holds a patent for a bradykinin B2-receptor antagonist peptide known as kinestatin. This peptide is isolated from the defensive skin secretion of toads. The structure of kinestatin is pGlu-Leu/Ile-Pro-Gly-Leu/Ile-Gly-Pro-Leu/Ile-Arg-NH. The patent also includes kinestatin analogs, prodrugs, fusion peptides, and multimeric peptides. These compounds can be utilized to treat and prevent disorders associated with bradykinin, including cardiovascular disorders, inflammation, asthma, allergic rhinitis, pain, and angiogenesis.

Career Highlights

Chris Shaw is affiliated with The Queen's University of Belfast, where he continues to engage in innovative research. His work has led to advancements in understanding how peptides can be used therapeutically. His dedication to research and development has positioned him as a key figure in his field.

Collaborations

Throughout his career, Chris has collaborated with esteemed colleagues such as David Hirst and Pingfan Rao. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries.

Conclusion

Chris Shaw's contributions to the field of pharmaceuticals through his innovative work on kinestatin exemplify the vital role of inventors in advancing medical science. His research not only highlights the importance of peptides in treatment but also underscores the collaborative nature of scientific discovery.